Á¦¾à ¾÷°è¿¡¼­ Àü·«Àû ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ RWE(Real-World Evidence)¸¦ Ȱ¿ë
Harnessing Real-World Evidence for Strategic Advantage in Pharma
»óǰÄÚµå : 1776188
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,268,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÌ º¸°í¼­´Â ÀǾàǰÀÇ ¶óÀÌÇÁ»çÀÌŬ¿¡¼­ RWE(Real-World Evidence)ÀÇ Àü·«Àû ÅëÇÕ¿¡ ´ëÇØ ÀÚ¼¼È÷ ´Ù·ç°í ÀÖÀ¸¸ç, º¸Á¶ÀûÀÎ µ¥ÀÌÅÍ ¼Ò½º¿¡¼­ ÀÇ»ç°áÁ¤ÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀ¸·ÎÀÇ ÁøÈ­¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ RWE ¼ö¿ë È®´ë, ÀÇ·á ±â¼ú Æò°¡¿¡¼­ RWEÀÇ ¿ªÇÒ, ½ÃÀå ÁøÀÔ ¹× »óȯ Àü·«¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ »ìÆìº¾´Ï´Ù. ¶ÇÇÑ, ½ÃÆÇ ÈÄ Á¶»çÀÇ °úÁ¦, ÅëÇÕµÈ µ¥ÀÌÅÍ »ýŰèÀÇ Çʿ伺, RWE »ý¼º¿¡ ÀÖ¾î AIÀÇ º¯È­ °¡´É¼º¿¡ ´ëÇØ¼­µµ ´Ù·ç°í ÀÖ½À´Ï´Ù. °­·ÂÇÑ RWE ¿ª·®À» ±¸ÃàÇϰí, ÁöºÒÀÚÀÇ ¿ä±¸¿¡ ¸Â°Ô ±Ù°Å¸¦ Á¶Á¤ÇÔÀ¸·Î½á Àü·«Àû ¼º°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ´Â ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

´äº¯µÈ ÁÖ¿ä Áú¹®

ÁÖ¿ä ±â¾÷

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

Âü¿© Àü¹®°¡ ÀϺΠ¸ñ·Ï

Á¶»ç ¹æ¹ý:

¼­·ù º¸°í¼­´Â µ¶ÀÚÀûÀÎ ¾÷°è Á¶»ç¿Í ¾÷°è ¿ÀÇǴϾ𠸮´õµé°úÀÇ ½ÉÃþ ÀÎÅͺ並 ÅëÇØ ¾òÀº µ¶¸³ÀûÀÌ°í °£°áÇÑ ºÐ¼®À» ¹ÙÅÁÀ¸·Î °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­´Â Á¦¾àȸ»ç °æ¿µÁøÀÌ ¾ÕÀ¸·Î ´Ù°¡¿Ã ±âȸ¿Í µµÀüÀ» °ü¸®Çϱâ À§ÇØ ÀÌÇØÇØ¾ß ÇÒ ÁÖ¿ä Æ®·»µå¿Í ½ÃÀå µ¿ÇâÀ» »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù. °¢ º¸°í¼­ÀÇ ÃÊÁ¡Àº 2Â÷ ¹®Çå °ËÅä¿Í È®ÀÎµÈ Áö½Ä °ÝÂ÷¸¦ ÅëÇØ Á¤Àǵ˴ϴÙ. ÀÌ Ãʱâ Á¶»ç¸¦ ¹ÙÅÁÀ¸·Î Áõ°Å¿¡ ±â¹ÝÇÑ Àü¹®°¡ Àǰ߰ú ÇÔ²² Åä·Ð °¡À̵带 ÀÛ¼ºÇÏ¿© Á¶»ç°¡ °¡Àå Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äÀ» ¾òÀ» ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÎÅÍºä ´ë»óÀÚ°¡ ÇØ´ç ÁÖÁ¦¿¡ ´ëÇØ À̾߱âÇÒ ¼ö ÀÖ´Â °æÇè, Áö½Ä, ÁöÀ§¸¦ °®Ãß°í ÀÖ´ÂÁö È®ÀÎÇϱâ À§ÇØ ¾ö°ÝÇÑ ½É»ç ±âÁØÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

¿ì¸® º¸°í¼­ÀÇ Æ¯Â¡Àº ¹«¾ùÀΰ¡?

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀ» ¹ÙÅÁÀ¸·Î °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ ¿¬±¸¿Í ÃÖ°íÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇп¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. 40°³ ÀÌ»óÀÇ ¿ªµ¿ÀûÀÎ Áúȯ ¿µ¿ªÀ» ´Ù·ç°í, KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report delves into the strategic integration of real-world evidence (RWE) across the pharmaceutical lifecycle, highlighting its evolution from a supplementary data source to a critical driver of decision-making. It examines the growing regulatory acceptance of RWE, its role in health technology assessments and its impact on market access and reimbursement strategies. The report also addresses the challenges of post-marketing surveillance, the need for cohesive data ecosystems and the transformative potential of AI in RWE generation. Gain insights into building robust RWE capabilities and aligning evidence with payer needs to enhance strategic outcomes.

Key Questions Answered:

Key Companies:

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

Partial List of Participating Experts:

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â